Evidence map›Paper›PMID 37830574›Full record

ArticleCells2023

Retinoid X Receptor Activation Prevents Diabetic Retinopathy in Murine Models.

Iuliia Dorofeeva, Assylbek Zhylkibayev, Irina V Saltykova, Venkatram Atigadda, Bibek Adhikari, Oleg S Gorbatyuk, Maria B Grant, Marina S Gorbatyuk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Iuliia DorofeevaDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Assylbek ZhylkibayevDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-9244-1505
Irina V SaltykovaDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Venkatram AtigaddaDepartment of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Bibek AdhikariDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-9615-8923
Oleg S GorbatyukDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Maria B GrantDepartment of Ophthalmology and Vision Sciences, Heersink School of Medicined, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Marina S GorbatyukDepartment of Optometry and Vision Science, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-9060-856X

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI James O Hill · 2000 to 2026
$31.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Stuart J Frank · 2013 to 2026
$19.5M
VISION SCIENCE RESEARCH CENTERP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAMLIN, PAUL DOUGLAS · 1985 to 2025
$15.4M
LXR as a Novel Therapeutic Target in Diabetic RetinopathyR01EY025383 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUSIK, JULIA V, GRANT, MARIA BARTOLOMEO · 2015 to 2024
$4.2M
Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancerR01CA276683 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Venkatram Reddy Atigadda · 2023 to 2026
$2.4M
Post-translational histone modification in ocular tissues of mice exposed to arsenicalsR01EY027763 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GORBATYUK, MARINA · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA276683NEI NIH HHS P30 EY003039NEI NIH HHS R01 EY025383NEI NIH HHS R01 EY027763NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Previously, the RXR agonist UAB126 demonstrated therapeutic potential to treat obese mice by controlling blood glucose levels (BGL) and altering the expression of genes associated with lipid metabolism and inflammatory response. The purpose of the study was to assess the effects of UAB126 on the progression of diabetic retinopathy (DR) in rodent models of type 1 diabetes (T1D), streptozotocin-induced, and type 2 diabetes (T2D), in db/db mice. UAB126 treatment was delivered either by oral gavage for 6 weeks or by topical application of eye drops for 2 weeks. At the end of the treatment, the retinal function of diabetic mice was assessed by electroretinography (ERG), and their retinal tissue was harvested for protein and gene expression analyses. Bone-marrow cells were isolated and differentiated into bone marrow-derived macrophages (BMDMs). The glycolysis stress test and the 2-DG glucose uptake analysis were performed. Our results demonstrated that in the UAB126-treated diabetic BMDMs, the ECAR rate and the 2-DG uptake were improved as compared to untreated diabetic BMDMs. In UAB126-treated diabetic mice, hyperglycemia was reduced and associated with the preservation of ERG amplitudes and enhanced AMPK activity. Retinas from diabetic mice treated with topical UAB126 demonstrated an increase in Rxr and Ppar and the expression of genes associated with lipid metabolism. Altogether, our data indicate that RXR activation is beneficial to preclinical models of DR.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic RetinopathyAnimalsDisease Models, AnimalMiceRetinoid X ReceptorsRetinoid X Receptorsdiabetic retinopathymurine modelretinoid X receptorUAB126

Identifiers

PMID37830574
PMCPMC10571672

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.